Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Allergan Inc., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in thousands

	Dec 31, 2014	Sep 30, 2014	Jun 30, 2014	Mar 31, 2014	Dec 31, 2013	Sep 30, 2013	Jun 30, 2013	Mar 31, 2013	Dec 31, 2012	Sep 30, 2012	Jun 30, 2012	Mar 31, 2012	Dec 31, 2011	Sep 30, 2011	Jun 30, 2011	Mar 31, 2011	Dec 31, 2010	Sep 30, 2010	Jun 30, 2010	Mar 31, 2010
Notes payable	72,100)	55,800)	60,900)	61,100)	55,600)	37,200)	51,600)	57,200)	48,800)	40,700)	42,400)	87,700)	83,900)	78,800)	76,100)	36,300)	28,100)	18,500)	13,100)	17,900)
Convertible notes	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	648,900)	642,500)	636,000)	629,700)	—)
Accounts payable	287,400)	283,200)	300,000)	316,500)	283,200)	267,800)	237,000)	218,500)	233,100)	210,600)	200,600)	203,000)	200,400)	190,100)	200,300)	200,500)	222,500)	206,300)	198,900)	257,900)
Accrued compensation	292,800)	267,900)	211,600)	168,100)	269,100)	241,900)	195,400)	156,500)	223,700)	204,900)	162,000)	129,500)	200,600)	186,900)	170,900)	118,800)	182,400)	169,100)	148,200)	98,400)
Accrued legal settlement expenses	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	609,900)	—)	—)
Other accrued expenses	905,000)	960,100)	833,900)	702,400)	597,500)	632,600)	610,300)	624,600)	589,600)	596,200)	558,800)	548,600)	470,100)	467,900)	474,200)	471,100)	436,800)	432,200)	386,900)	388,400)
Income taxes	—)	—)	—)	—)	38,900)	16,900)	—)	—)	—)	2,500)	—)	—)	—)	—)	—)	—)	16,100)	21,000)	43,200)	20,700)
Liabilities of discontinued operations	—)	—)	—)	—)	—)	3,300)	3,600)	4,700)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Current liabilities	1,557,300)	1,567,000)	1,406,400)	1,248,100)	1,244,300)	1,199,700)	1,097,900)	1,061,500)	1,095,200)	1,054,900)	963,800)	968,800)	955,000)	923,700)	921,500)	1,475,600)	1,528,400)	2,093,000)	1,420,000)	783,300)
Long-term debt, excluding current maturities	2,085,300)	2,088,600)	2,091,800)	2,095,100)	2,098,300)	2,101,500)	2,104,600)	2,107,700)	1,512,400)	1,515,500)	1,514,900)	1,514,700)	1,515,400)	1,516,200)	1,510,300)	1,529,500)	1,534,200)	1,546,000)	888,700)	877,800)
Long-term convertible notes	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	623,500)
Other liabilities	1,010,100)	871,200)	698,300)	752,000)	762,200)	730,300)	725,200)	718,900)	709,100)	746,200)	733,300)	719,800)	705,800)	615,600)	459,100)	477,500)	464,400)	416,700)	369,200)	377,100)
Non-current liabilities	3,095,400)	2,959,800)	2,790,100)	2,847,100)	2,860,500)	2,831,800)	2,829,800)	2,826,600)	2,221,500)	2,261,700)	2,248,200)	2,234,500)	2,221,200)	2,131,800)	1,969,400)	2,007,000)	1,998,600)	1,962,700)	1,257,900)	1,878,400)
Total liabilities	4,652,700)	4,526,800)	4,196,500)	4,095,200)	4,104,800)	4,031,500)	3,927,700)	3,888,100)	3,316,700)	3,316,600)	3,212,000)	3,203,300)	3,176,200)	3,055,500)	2,890,900)	3,482,600)	3,527,000)	4,055,700)	2,677,900)	2,661,700)
Preferred stock, $.01 par value; none issued	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock, $.01 par value	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)	3,100)
Additional paid-in capital	3,353,700)	3,249,700)	3,193,400)	3,124,700)	3,032,800)	3,005,200)	2,975,600)	2,951,200)	2,900,600)	2,854,100)	2,824,200)	2,794,100)	2,761,800)	2,725,500)	2,702,400)	2,828,800)	2,815,500)	2,774,800)	2,751,700)	2,736,200)
Accumulated other comprehensive loss	(408,600)	(293,400)	(216,100)	(224,000)	(226,600)	(252,100)	(282,100)	(265,900)	(244,600)	(244,800)	(258,600)	(218,500)	(241,400)	(179,000)	(100,300)	(131,600)	(152,900)	(105,400)	(166,300)	(122,800)
Retained earnings	5,894,800)	5,411,900)	5,138,800)	4,790,500)	4,646,700)	4,363,600)	4,089,400)	3,761,900)	3,832,100)	3,602,900)	3,387,600)	3,134,900)	2,969,300)	2,752,200)	2,530,300)	2,342,300)	2,225,900)	2,030,200)	2,723,000)	2,498,700)
Treasury stock, at cost	(1,090,000)	(1,260,600)	(1,333,200)	(1,076,400)	(992,800)	(1,033,900)	(1,064,100)	(1,113,200)	(654,100)	(645,700)	(517,500)	(255,000)	(183,200)	(196,100)	(171,600)	(176,900)	(133,900)	(243,200)	(223,500)	(170,400)
Total Allergan, Inc. stockholders’ equity	7,753,000)	7,110,700)	6,786,000)	6,617,900)	6,463,200)	6,085,900)	5,721,900)	5,337,100)	5,837,100)	5,569,600)	5,438,800)	5,458,600)	5,309,600)	5,105,700)	4,963,900)	4,865,700)	4,757,700)	4,459,500)	5,088,000)	4,944,800)
Noncontrolling interest	10,000)	8,300)	8,300)	7,100)	6,300)	27,200)	25,400)	25,300)	25,500)	24,700)	22,600)	22,300)	22,800)	22,800)	24,800)	22,400)	23,400)	24,900)	21,700)	21,900)
Total equity	7,763,000)	7,119,000)	6,794,300)	6,625,000)	6,469,500)	6,113,100)	5,747,300)	5,362,400)	5,862,600)	5,594,300)	5,461,400)	5,480,900)	5,332,400)	5,128,500)	4,988,700)	4,888,100)	4,781,100)	4,484,400)	5,109,700)	4,966,700)
Total liabilities and equity	12,415,700)	11,645,800)	10,990,800)	10,720,200)	10,574,300)	10,144,600)	9,675,000)	9,250,500)	9,179,300)	8,910,900)	8,673,400)	8,684,200)	8,508,600)	8,184,000)	7,879,600)	8,370,700)	8,308,100)	8,540,100)	7,787,600)	7,628,400)

The financial data exhibits several notable trends in liabilities and equity over the observed quarterly periods.

Notes payable: The notes payable show a fluctuating pattern, starting at 17,900 thousand USD in March 2010, peaking at 83,900 thousand USD in December 2010, and demonstrating volatility thereafter, ending at a higher level of 72,100 thousand USD in December 2014 compared to the beginning.
Convertible notes and Long-term convertible notes: Convertible notes appear distinctly only in mid-2010 to early 2011, with values near 630 million USD, then no reported values in subsequent periods. Long-term convertible notes are reported only in March 2010 at approximately 623 million USD and then discontinued, suggesting a refinancing or reclassification event occurred.
Accounts payable: Accounts payable trends show moderate increases over the period, starting around 258 million USD in March 2010 and gradually rising to approximately 287 million USD by December 2014. The trend indicates a generally stable but slightly increasing level of short-term obligations to suppliers or vendors.
Accrued compensation: Accrued compensation displays cyclicality within each year, with peaks generally occurring in the fourth quarter and troughs in the first quarter, reflecting seasonality in expenses. Despite fluctuations, overall accrued compensation increased from 98.4 million USD in Q1 2010 to 292.8 million USD by Q4 2014, indicating growth in compensation liabilities.
Accrued legal settlement expenses: A significant accrual occurs only in the third quarter of 2010 at approximately 610 million USD, implying a substantial legal cost was recognized that quarter but not carried forward, possibly indicating settlement resolution.
Other accrued expenses: Other accrued expenses steadily increase over time, starting near 388 million USD in Q1 2010, reaching a peak around 960 million USD in Q3 2014, before slightly declining again. This suggests growing operational liabilities in this category.
Income taxes: Income tax liabilities are inconsistently reported, with certain quarters showing moderate amounts (for example, 43.2 million USD in Q2 2010 and 38.9 million USD in Q1 2014), but generally absent in other periods, indicative of variable tax obligations or timing differences.
Current liabilities: There is pronounced volatility in current liabilities, including a notable peak of 2.09 billion USD in Q3 2010, followed by fluctuations and an upward trend towards 1.56 billion USD in Q4 2014. This variability may reflect changes in short-term financing or operational cycles affecting current obligations.
Long-term debt, excluding current maturities: Long-term debt remains relatively stable around 1.5 billion USD in the early periods but increases significantly to about 2.1 billion USD starting in 2013, maintaining that higher level through 2014, indicating new borrowings or refinancing with additional debt.
Other liabilities and Non-current liabilities: Other liabilities show growth overall, rising from approximately 377 million USD in Q1 2010 to over 1 billion USD by Q4 2014, with some fluctuations. Non-current liabilities mirror this trend, growing from about 1.88 billion USD to over 3.09 billion USD throughout the period, highlighting increasing long-term obligations.
Total liabilities: Total liabilities reveal substantial growth, particularly with a surge in Q3 2010 to over 4 billion USD, followed by fluctuations and an upward trajectory reaching approximately 4.65 billion USD by Q4 2014. This trend reflects increased leverage or expanded liabilities in various categories over the years.
Equity components: Common stock remains constant at 3.1 million USD, suggesting no new stock issuances or retirements at par value. Additional paid-in capital consistently increases from about 2.74 billion USD to over 3.35 billion USD, indicating ongoing capital contributions or stock-based transactions.
Accumulated other comprehensive loss: Accumulated other comprehensive loss fluctuates, showing an increasing negative balance reaching approximately -408.6 million USD by Q4 2014 from a starting point of -122.8 million USD in Q1 2010, implying growing unrealized losses or adjustment items affecting equity.
Retained earnings: Retained earnings reflect a strong positive trend, growing from approximately 2.5 billion USD to nearly 5.9 billion USD over the period, indicating consistent profitability and earnings retention within the company.
Treasury stock, at cost: Treasury stock values display considerable volatility, with a marked increase in cost from about 170 million USD to over 1.1 billion USD (negative value) indicating significant share repurchases, especially between 2011 and 2013, followed by some reduction thereafter.
Total stockholders’ equity and Total equity: Total stockholders’ equity increases steadily from around 4.94 billion USD in early 2010 to 7.75 billion USD at the end of 2014, corroborated by total equity figures following a similar trajectory. This overall growth signals strengthening equity positions despite negative comprehensive losses and treasury stock fluctuations.
Total liabilities and equity: The sum of total liabilities and equity expands consistently from approximately 7.63 billion USD to over 12.4 billion USD, demonstrating company growth in scale and capitalization over the period analyzed.

In conclusion, the financial data reveals significant growth in both liabilities and equity components, characterized by increasing long-term debt, rising accrued expenses, and enhanced retained earnings. The company exhibits expanded leverage alongside augmented equity financing, reflecting strategic financial management that supports growing operations and shareholder value. Seasonal variations and one-off items such as legal settlements contribute to some volatility observed in specific accounts.

Download chart

Allergan Inc. (NYSE:AGN.)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data